Cargando…
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are...
Autores principales: | Zhang, Xi-Wen, Wu, Yi-Shi, Xu, Tian-Min, Cui, Man-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046142/ https://www.ncbi.nlm.nih.gov/pubmed/36979400 http://dx.doi.org/10.3390/biom13030465 |
Ejemplares similares
-
CAR-T cell therapy for lung cancer: a promising but challenging future
por: Zhong, Shupeng, et al.
Publicado: (2020) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Aparicio, Cristina, et al.
Publicado: (2021) -
CAR-T cell therapy in ovarian cancer: from the bench to the bedside
por: Zhu, Xinxin, et al.
Publicado: (2017) -
Clinical manufacturing of CAR T cells: foundation of a promising therapy
por: Wang, Xiuyan, et al.
Publicado: (2016) -
CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)